Incidence and survival of retinoblastoma in the Netherlands: a register based study 1862–1995

Annette C Moll, D Joop Kuik, Lex M Bouter, Willem Den Otter, P Dick Bezemer, Jan Willem Koten, Saskia M Imhof, Bertus P Kuyt, Karel E W P Tan

Abstract

Aim—The aim of this study was to determine the (time trends in) incidence and survival of hereditary (familial and sporadic) and non-hereditary retinoblastoma for male and female patients born in the Netherlands between 1862 and 1995.

Method—The national retinoblastoma register was updated and now consists of 955 patients. The missing dates of death were obtained from the municipal registers and the Central Bureau of Genealogy in The Hague. Mortality was compared with the Dutch vital statistics.

Results—From 1862 to 1995 no significant differences in incidence for retinoblastoma were found in the hereditary subgroups. Further, no significant differences between males and females were found, both overall and in the hereditary subgroups. The average incidence of retinoblastoma increased until 1944, probably due to incompleteness of the register, and stabilised after 1945 (1 per 17 000 live births). From 1990 to 1995 the standardised mortality ratio increased for hereditary retinoblastoma patients from 2.9 to 9.0 and decreased for non-hereditary retinoblastoma patients from 1.9 to 1.0.

Conclusion—Although survival for retinoblasta was significantly better after 1945 than before, in comparison with the Dutch population the mortality between 1900 and 1990 increased for the hereditary and decreased for the non-hereditary retinoblastoma patients.

Retinoblastoma is a rare paediatric eye tumour which occurs in a hereditary and a non-hereditary form. All bilateral (familial or sporadic) and familial unilateral cases can be considered to be hereditary (30%–40% of the cases). In familial cases the patient inherits the retinoblastoma mutation from a carrier parent and in sporadic bilateral cases from a healthy parent in whom a new germinal mutation has occurred.

The incidence of retinoblastoma reported in the literature ranges from 1:10 000 in South Africa to 1:34 000 in the Netherlands (Table 1). These extreme values come from hospital populations and are based on very crude estimations and are therefore probably inaccurate. During the past years it has often been discussed whether there has been any change in the incidence of this malignant disease. The survival rate of retinoblastoma improved in the last century, mostly because of Wardrop’s recommendation to enucleate a retinoblastoma eye. As a consequence, hereditary retinoblastoma patients were able to have offspring and this presumably led to a gradual increase in the incidence of hereditary retinoblastoma in the population.

Furthermore, there is still a discussion in the literature regarding the sex predominance of retinoblastoma patients. Pendergrass and Davis found no difference in the incidence of retinoblastoma between males and females. Naumova and Sapienza found a significant overrepresentation of males among bilateral sporadic cases.

Neel and Vogel discussed a possible viral aetiology of retinoblastoma. A seasonal variation in births of children with non-hereditary retinoblastoma would suggest that the incidence is possibly influenced by certain environmental agents such as viral infection.

The National Retinoblastoma Register of the Netherlands offers the unique opportunity to analyse the above mentioned controversies in the literature. Therefore, the purposes of this study were to determine for hereditary (sporadic and familial) and non-hereditary retinoblastoma patients: (1) the (time trends in) incidence, (2) the difference in incidence between males and females, (3) the difference in incidence between different months, (4) time trends in survival, (5) the difference in survival between male and female patients.

Methods

The National Retinoblastoma Register of the Netherlands was used in the updated version. It can be regarded as virtually complete for patients born from 1945 to date. We gathered the dates of birth and death of the 955 registered Dutch retinoblastoma patients born from 1862 to 1995. If possible, missing dates of death of patients were obtained with the help of the municipal registers and the Central Bureau of Genealogy in The Hague.

Retinoblastoma was regarded to be hereditary if at least one of the following criteria was met: bilateral retinoblastoma, family history for retinoblastoma (then the parent would be carrier of the defect in the retinoblastoma gene), or a defect in the retinoblastoma gene was found in chromosomal/DNA analysis of the patient. Some sporadic unilateral retinoblastoma pa-
Table 1 Incidence figures of retinoblastoma cited in the literature

<table>
<thead>
<tr>
<th>Population</th>
<th>Time period</th>
<th>No of cases</th>
<th>Incidence*</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bantu, South Africa</td>
<td>1955-75</td>
<td>80</td>
<td>1:10 000</td>
<td>Freedman and Goldberg, 1976*</td>
</tr>
<tr>
<td>Malawi</td>
<td>1975</td>
<td>20</td>
<td>1:10 000</td>
<td>BenEfraim and Chirambo, 1976*</td>
</tr>
<tr>
<td>America</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td>1969-71</td>
<td>59</td>
<td>1:18 000</td>
<td>Devesa, 1975†</td>
</tr>
<tr>
<td>Michigan, USA</td>
<td>?</td>
<td>49</td>
<td>1:20 000</td>
<td>Falls and Neel, 1951†</td>
</tr>
<tr>
<td>Ohio, USA</td>
<td>?</td>
<td>126</td>
<td>1:24 000</td>
<td>Macklin, 1961†</td>
</tr>
<tr>
<td>USA</td>
<td>1974-6</td>
<td>70</td>
<td>1:18 000</td>
<td>Pendergrass and Davis, 1980†</td>
</tr>
<tr>
<td>Asia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hokkaido, Japan</td>
<td>1945-57</td>
<td>69</td>
<td>1:24 000</td>
<td>Matsunaga and Ogyu, 1959†</td>
</tr>
<tr>
<td>Nagasaki, Japan</td>
<td>1965-86</td>
<td>34</td>
<td>1:16 000</td>
<td>Takano et al, 1991†</td>
</tr>
<tr>
<td>Australia, New Zealand</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Zealand</td>
<td>1948-77</td>
<td>100</td>
<td>1:18 000</td>
<td>Suckling et al, 1982†</td>
</tr>
<tr>
<td>Australia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Denmark</td>
<td>1928-57</td>
<td>118</td>
<td>1:19 000</td>
<td>Bech and Jensen, 1961‡</td>
</tr>
<tr>
<td>Finland</td>
<td>1950-64</td>
<td>?</td>
<td>1:16 000</td>
<td>Tarkkanen and Tuovinen, 1971‡</td>
</tr>
<tr>
<td>France</td>
<td>1951-60</td>
<td>295</td>
<td>1:28 000</td>
<td>Briard-Guillemot et al, 1974‡</td>
</tr>
<tr>
<td>Germany</td>
<td>1934-51</td>
<td>48</td>
<td>1:29 000</td>
<td>Vogel, 1979</td>
</tr>
<tr>
<td>Great Britain</td>
<td>1962-80</td>
<td>431</td>
<td>1:23 000</td>
<td>Sanders et al, 1988‡</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>1927-9</td>
<td>?</td>
<td>1:34 000</td>
<td>Hemmes, 1931‡</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>1945-70</td>
<td>486</td>
<td>1:16 000</td>
<td>DeKinderen et al, 1990†</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>1938-56</td>
<td>23</td>
<td>1:27 000</td>
<td>Stevenson and Martin, 1957†</td>
</tr>
<tr>
<td>Norway</td>
<td>1950-73</td>
<td>75</td>
<td>1:17 000</td>
<td>Herveen, 1973</td>
</tr>
<tr>
<td>Sweden</td>
<td>1958-71</td>
<td>88</td>
<td>1:18 000</td>
<td>Kock and Neaeer, 1973†</td>
</tr>
<tr>
<td>Middle East</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Riyadh, Saudi Arabia</td>
<td>1982-6</td>
<td>22</td>
<td>1:12 000</td>
<td>Al-Idrissi et al, 1991‡</td>
</tr>
</tbody>
</table>

*Incidence in number of retinoblastoma patients per live births.

SMR of 1.25 for example means 25% ‘extra mortality’ in the retinoblastoma patients in comparison with the Dutch population.35 The Dutch mortality rates in age groups per calendar year of death were available from 1900 to date.34 Confidence intervals (95% CI) were calculated using the logarithm of the SMR.32 In order to detect a trend in the SMR from 1900 to 1995 regression analyses on the logarithm of the SMR were done. This project was approved by the medical ethics committee of the Free University Hospital, Amsterdam, the Netherlands.

Results

HEREDITY

Sex and heredity of the retinoblastoma patients are shown in Table 2. Forty nine of the 350 hereditary retinoblastoma patients (14%) had the unilateral form; 320 of the 635 unilateral tumours were sited in the right eye and 296 in the left eye; in 19 unilateral cases the location of the tumour was unknown. The retinoblastoma subcohort 1945–94 has nearly the same composition as the total cohort (data not shown).

INCIDENCE BY SEX

In the period 1862–1995, no significant difference was found in incidence for retinoblastoma between males and females in the retinoblastoma subgroups (sporadic hereditary, familial hereditary, and non-hereditary). Furthermore, our investigation did not reveal any significant difference between the male/female ratio in various retinoblastoma subgroups and the Dutch population. Moreover, in the subcohort 1945–94 no significant difference in male/female ratio was found between the different retinoblastoma subgroups, or compared with the Dutch population (data no shown).

TIME TRENDS IN INCIDENCE

Figure 1 shows the number of retinoblastoma patients per 100 000 life births in 5 year cohorts in the Netherlands. The incidence of retinoblastoma increased significantly from 1862 to 1945. After 1945 there was no evidence of an increase in the total incidence of retinoblastoma, nor was there any significant change in incidence in the retinoblastoma subgroups (sporadic hereditary, familial hereditary, and non-hereditary retinoblastoma; data not shown). The average incidence of retinoblastoma after 1945 was 1:17 000 (95% CI; 1:15 500–1:18 500) (5.8 per 100 000) live births (range 13 000–25 000).

Table 2 Sex and heredity of patients in the National Retinoblastoma Register of the Netherlands from 1862 to 1995

<table>
<thead>
<tr>
<th>Group</th>
<th>Male (%)</th>
<th>Female (%)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-hereditary</td>
<td>318 (54.3)</td>
<td>268 (45.7)</td>
<td>586</td>
</tr>
<tr>
<td>Sporadic hereditary</td>
<td>130 (52.2)</td>
<td>119 (47.8)</td>
<td>249*</td>
</tr>
<tr>
<td>Familial hereditary</td>
<td>47 (46.5)</td>
<td>54 (53.5)</td>
<td>101†</td>
</tr>
<tr>
<td>Unknown</td>
<td>8</td>
<td>11</td>
<td>19</td>
</tr>
<tr>
<td>Total</td>
<td>503 (52.7)</td>
<td>452 (47.3)</td>
<td>955</td>
</tr>
</tbody>
</table>

*Including 29 unilateral patients.
†Including 20 unilateral patients.
In all, 287 of the 955 patients born between 1862 and 1995 had died; 640 patients were still alive and 28 patients could not be traced for follow up. Five hundred and thirty eight patients of the subcohort 1945–94 were still alive; 99 patients had died and eight patients could not be traced for follow up.

The survival at 5 years (p<0.01) and 35 years (p<0.01) of age was significantly better for patients born after 1945 than for patients born before 1945. SMRs for the period 1898–1995 are given in Table 4. No trend in the SMR could be found for the total group of patients.

**INCIDENCE PER MONTH**

The distribution of the retinoblastoma subgroups does not show significant differences over the 12 months of the year in comparison with the Dutch population. There appears to be a slight, but not significant excess of retinoblastoma affected newborns from December to May (data not shown).

**SURVIVAL**

In all, 287 of the 955 patients born between 1862 and 1995 had died; 640 patients were still alive and 28 patients could not be traced for follow up. Five hundred and thirty eight patients of the subcohort 1945–94 were still alive; 99 patients had died and eight patients could not be traced for follow up. Cumulative survival at 5 and 35 years of age for the different retinoblastoma subgroups is shown in Table 3. There was a significant difference in cumulative survival between hereditary and non-hereditary retinoblastoma (p<0.005). The difference in survival between sporadic hereditary and familial hereditary survival was not significant. The difference in survival between male and female retinoblastoma patients was also not statistically significant.

The survival at 5 years (p<0.01) and 35 years (p<0.01) of age was significantly better for patients born after 1945 than for patients born before 1945. SMRs for the period 1898–1995 are given in Table 4. No trend in the SMR could be found for the total group of patients. However, for the hereditary patients the SMR increased significantly (p=0.007), while for the non-hereditary patients a significant decrease trend was found (p=0.017).

**Discussion**

**HEREDITY**

The percentage of hereditary and non-hereditary retinoblastoma (61.4% and 36.6%, respectively) was similar to the percentage published by Vogel. In addition, he found that 10%–12% of the unilateral sporadic cases were in fact new germline mutants; we found a nearly similar percentage of 14.0.

**INCIDENCE BY SEX**

Several studies showed no sex differences in the incidence of retinoblastoma. Nau-mova and Sapienza made an extensive compilation of the literature regarding sex and laterality of proved sporadic cases and found a significant overrepresentation of males among bilateral sporadic cases. For unilateral retinoblastoma they could not find such a difference. We could not confirm their first mentioned findings.

**TIME TRENDS IN INCIDENCE**

As discussed by Vogel studies covering more recent periods tend to give higher values of incidence of retinoblastoma. The most obvious explanation is a more complete ascertainment in the more recent studies. This can also explain the increasing incidence we found in the period 1862–1944. It seems that especially in the period 1862–1900 the tumour was often not recognised and/or registered. Vogel did not exclude that there has been a true increase in incidence of retinoblastoma. However, the incidence in the period 1945–94 did not change significantly in our study. Probably, in this period the tumour was diagnosed correctly and the register was really complete.

**INCIDENCE PER MONTH**

Earlier reports failed to show clustering of sporadic hereditary or non-hereditary retinoblastoma in specific months. Our data revealed fluctuations to some extent by month of birth, but this was not statistically significant.

**SURVIVAL**

In 1809, Wardrop advocated enucleation of a retinoblastoma containing eye as a lifesaving measure. It is the general opinion that early enucleation contributed to a better survival. However, new treatment modalities (irradiation...
tion or coagulation) were developed to save life and preserve vision. Bishop and Madsen reported an increase in the survival of retinoblastoma of 5% in 1869 to 81% in 1967. This study also showed an increasing survival. It should be stressed also that from 1900 the survival in the general population increased dramatically. Taking this into account, it is clear from the trend analysis of the SMR that survival for the hereditary group could not follow the improvement in the general population.

The risk of death is significantly higher for a retinoblastoma patient than for an average member of the Dutch population, as all SMRs are larger than 1. In other words, the improved diagnostic technique and improved retinoblastoma treatment did not result in the same length of survival for the general Dutch population and patients with hereditary retinoblastoma, in particular. Mortality increased significantly compared with the mortality of the general population (p=0.007). In contrast, there was a significantly decreased 'extra mortality' of the non-hereditary patients (p=0.017). These findings can probably be explained by the hereditary retinoblastoma gene disorder. Hereditary retinoblastoma patients are vulnerable for second primary tumours and pineoblastomas. Furthermore, treatment of hereditary (bilateral) retinoblastoma patients is more often irradiation than that of non-hereditary patients, because non-hereditary patients are mostly enucleated. DerKinderen et al. have shown that irradiation therapy is an extra risk factor for second primary tumours in hereditary retinoblastoma patients. This will lead to death in many cases. On the other hand no second primary tumours were induced by irradiation of non-hereditary retinoblastoma patients; consequently, non-hereditary retinoblastoma patients will be cured and survival will be improved.

This study was supported by grants from the Haak-Bastiaanse-Kuneman-stichting.